Clinical and Economic Burden of Cardiac Implantable Electronic Device (CIED) Infections

 

Current Situation

  • Infection rates are increasing faster than CIED implant rates1
  • Infection rates typically range from 0.6% to 4% but have been reported as high as 7%2,3,4,5 
  • Average hospital length of stay (LOS) ranges from 15.5 to 24.3 days7
  • In-hospital patient mortality associated with a CIED infection ranges from 4.6% to 11.3%7
  • 15 month patient mortality ranges from 27% to 35%7
  • The average cost to treat a CIED infection is $146,0008
  • AIGISRx® stabilizes CIEDs and offers site-specific, sustained antibiotic delivery
  • Future governmental legislation could increase visibility and importance of preventing infections

Estimated Costs Associated with Major CIED Infections at Different Infection Rates (1-7%)6

 

Estimated Costs Associated with Major CIED Infections at Different Infection Rates (1-7%)6

 

To further assist our customers as they consider the clinical and financial value of AIGISRx, the following information is shared for educational and strategic planning purpose only.

Indication For Use - AIGISRx is intended to securely hold a pacemaker pulse generator or defibrillator in order to create a stable environment when implanted in the body. AIGISRx contains the antimicrobial agents, rifampin and minocyline, which have been shown to reduce infection in an in vivo model of bacterial challenge following surgical implantation of the generator or defibrillator.9  This device is only intended to be used in conjunction with pacemakers and implantable defibrillators.

Physicians, administrators, and coders all agree that coding the professional & technical components of procedures rely upon details provided in the patients medical record. While TYRX believes this information to be correct, providers are encouraged to check with their payers .

 

Facility Considerations* include but are not limited to:

  1. Voigt et al. PACE 2010 33(4):414-419
  2. Klug et al. Circulation 2007 116(12):1349-1355
  3. Gould et al. Heart Rhythm 2008 5(12):1675-1681
  4. De Oliveira, J.C. et al. Circulation Arrhythmia Electrophysiology 2009 2(1):29-34
  5. Tarakji et al. Heart Rhythm 2010 7(8):1043-1047 
  6. Based on TYRX analysis of the Medicare Standard Analytic File (SAF) for 2008 inpatient claims, performed in conjunction with the health care consulting firm Braide-Forbes Health Research
  7. Sohail et al. Archives of Internal Medicine ePub Sept. 12, 2011
  8. Greenspon et al. JACC 2011;58,(10)1001-1006
  9. Based upon preclinical in vitro and in vivo data. Data on file at TYRX and published in PACE 2009 32(7):898-907